Ever since Zimmer agreed to purchase Biomet for $13.4 billion in April 2014, the wait for takeover of Smith & Nephew has been on, with Stryker being the most likely acquirer. Rumors of an impending deal were just renewed by a StreetInsider report that Stryker has put an $18 billion offer for Smith & Nephew on the table, sending its stock up as much as 6%.
Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to the deal, who told the newspaper the Dublin drugmaker expects to ink a pact or walk away "reasonably soon."
AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.
AstraZeneca is buying big into the promise of Acerta Pharma's in-development blood cancer therapy, signing on to buy a majority stake in the company in a deal that could be worth up to $7 billion.
The private equity owners of CRO giant PPD are looking to either sell the company or take it public, according to Reuters, moves that would follow a trend in the pharma contracting industry.
Is the swap destined to be pharma's next M&A trend? When dealmakers tot up the advantages of Sanofi and Boehringer Ingelheim's asset-trade talks--and add them to the big GlaxoSmithKline-Novartis swap-out earlier this year--they might follow up with barter arrangements of their own, M&A experts say.
The consumer health space is consolidating rapidly--and Bayer knows it. It also knows its whopper $14.2 billion deal for Merck & Co.'s consumer business last year isn't going to be enough to keep it on the OTC leaderboard.
Capsulemaker and drug formulation specialist Capsugel is adding to its manufacturing and broadening its dosing form capabilities with a deal to buy not one but two different companies and pick up 210 employees in the process.
Novartis and GlaxoSmithKline may have started a trend with their big sale-and-swap announced last year. Now, it's Sanofi and Boehringer Ingelheim working on a trade, with the French drugmaker's animal health business moving to Boehringer in exchange for the latter's consumer healthcare unit.
The tax benefits of buying Allergan are Pfizer's No. 1 reason for doing the $160 billion deal. In fact, some analysts see the $2 billion in potential tax savings as the merger's only substantial advantage.